As a tenured Professor with over ten years of academic research experiences and seven years of biopharmaceutical industrial experiences, Dr. X. Margaret Liu has established multiple projects in different research fields such as targeted cancer therapy, drug delivery, innovative technologies development, biomanufacturing, and anti-cancer efficacy evaluation in various preclinical animal models. Her current research projects include antibody-drug conjugates to treat such as triple-negative breast cancer (TNBC), lung cancer and neuroendocrine cancer, mitochondria-targeted gene therapy to treat TNBC, lung cancer, and glioblastoma, targeted drug delivery, and bioprocessing and biomanufacturing. She is working on the development of combined mitochondrial gene therapy/chemotherapy, new monoclonal antibody development and engineering (humanization), dual-targeting and dual-payload antibody-drug conjugates, and new cancer therapeutic technologies. Her research also aims to move forward to translational studies and therapy commercialization.